Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
- 1 December 2012
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (12) , 1918-1926
Abstract
This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituximab concentration data were well described by a 2‐compartment model comprising a time‐varying clearance component related to the target‐mediated clearance pathway and a constant clearance component reflecting catabolic elimination pathway. Marked differences were observed compared to pharmacokinetic parameters for non‐Hodgkin lymphoma (NHL) obtained previously: in CLL, time‐varying clearance at time zero (CL2) was faster, volumes of distribution (V1 and V2) were larger, and rate of change (Kdes) from the target‐mediated clearance pathway to catabolic elimination was lower than NHL. Fludarabine and cyclophosphamide disposition showed no apparent change when co‐administered with rituximab. A positive correlation between pharmacokinetic parameters and clinical response was observed, supporting the use of the higher rituximab dose of 500 mg/m2 in CLL patients (vs 375 mg/m2 in NHL) to achieve an effective clinical response.Keywords
This publication has 27 references indexed in Scilit:
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- RituximabDrugs, 2010
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaBlood, 2010
- Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20Blood, 2009
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative DisordersJournal of Clinical Oncology, 2005
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood, 2003
- Cellular and Clinical Pharmacology of FludarabineClinical Pharmacokinetics, 2002